Clinical trials in Munich – page 64

1 191 clinical trials in Munich, Germany across 8 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Munich at a glance

1 191

clinical trials

Research sites8

Quick filters

1 191 trials in Munich

Open in trial search

Impaired gastric emptying+1

Not recruiting

Study on the Safety and Effectiveness of Naronapride for Adults with Moderate Idiopathic or Diabetic Gastroparesis

Investigational

Study on the Safety and Effectiveness of Naronapride for Adults with Moderate Idiopathic or Diabetic Gastroparesis

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Naronapride Dihydrochloride Trihydrate
Sponsor:Dr. Falk Pharma GmbH

Contact Research Centre

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Gilteritinib
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Anal cancer stage II+1

Not recruiting

Study on Durvalumab with Radiochemotherapy for Patients with Locally-Advanced Anal Cancer

Registered drugNo placebo

Study on Durvalumab with Radiochemotherapy for Patients with Locally-Advanced Anal Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Goethe University Frankfurt

Contact Research Centre

Gastrooesophageal cancer+1

Not recruiting

Study on Organ Preservation for Early Stage Esophageal Cancer Using Durvalumab and Chemoradiation for Patients Eligible for Surgery

Registered drugNo placebo

Study on Organ Preservation for Early Stage Esophageal Cancer Using Durvalumab and Chemoradiation for Patients Eligible for Surgery

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Renal failure

Not recruiting

Study of RMC-035 to prevent kidney injury in patients undergoing open-chest heart surgery

Investigational

Study of RMC-035 to prevent kidney injury in patients undergoing open-chest heart surgery

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Rmc-035
Sponsor:Guard Therapeutics International AB (publ)

Contact Research Centre

Facioscapulohumeral muscular dystrophy

Not recruiting

Study on the Effectiveness and Safety of Losmapimod for Patients with Facioscapulohumeral Muscular Dystrophy (FSHD)

Investigational

Study on the Effectiveness and Safety of Losmapimod for Patients with Facioscapulohumeral Muscular Dystrophy (FSHD)

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Losmapimod
Sponsor:Fulcrum Therapeutics Inc.

Contact Research Centre

Pemphigoid

Not recruiting

Study of dupilumab effectiveness compared to placebo in adults with bullous pemphigoid

Registered drug

Study of dupilumab effectiveness compared to placebo in adults with bullous pemphigoid

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Dupilumab
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Myotonic dystrophy

Not recruiting

Study on AOC 1001 for Treating Myotonic Dystrophy Type 1 in Patients

Investigational

Study on AOC 1001 for Treating Myotonic Dystrophy Type 1 in Patients

Investigational

Germany

Participants:0–17 years · 18–64 years
Substances:Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dmpk Via A Non-Cleavable Linker
Sponsor:Avidity Biosciences Inc.

Contact Research Centre

Neoplasm

Not recruiting

Study on NECVAX-NEO1 with PD-1/PD-L1 Inhibitors for Patients with Advanced Solid Tumors

InvestigationalNo placebo

Study on NECVAX-NEO1 with PD-1/PD-L1 Inhibitors for Patients with Advanced Solid Tumors

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Necvax-Neo1
Sponsor:NEC Bio Therapeutics GmbH

Contact Research Centre

Hidradenitis

Not recruiting

Study on Long-Term Safety and Effectiveness of Bimekizumab for Adults with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo

Study on Long-Term Safety and Effectiveness of Bimekizumab for Adults with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bimekizumab
Sponsor:UCB Biopharma

Contact Research Centre

Polycythaemia vera+1

Not recruiting

Study of Ruxolitinib for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia

Registered drugNo placebo

Study of Ruxolitinib for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Ruxolitinib
Sponsor:Universitaetsklinikum Aachen AöR

Contact Research Centre

Peripheral T-cell lymphoma unspecified

Not recruiting

Study of Lacutamab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Registered drugNo placebo

Study of Lacutamab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Gemcitabine
Sponsor:LYSARC

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Munich

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on various cancer types, including metastatic prostate cancer, colorectal cancer, and bladder cancer. Novel therapeutic approaches combining immunotherapy with established treatments are being investigated.

Prostate Cancer Treatment Innovations
Colorectal Cancer Therapies
Early-Stage Bladder Cancer Management

Research aims to improve survival rates and treatment effectiveness through targeted therapies and immunological approaches.

02 Cardiovascular and Hematological Studies

Important research in heart disease and blood conditions, including studies on TTR amyloidosis and prevention of thrombotic events. Novel medications are being tested to improve patient outcomes.

Cardiac Amyloidosis Treatment
Thrombosis Prevention
Cardiovascular Disease Management

Focus on developing innovative treatments for complex cardiovascular conditions and preventing blood clots.

03 Neurology and Mental Health

Advanced research into neurological conditions, particularly focusing on Alzheimer's disease and autoimmune dementia. Studies aim to develop new therapeutic approaches and improve diagnostic tools.

Early-Stage Alzheimer's Treatment
Autoimmune Dementia Therapy
Cognitive Function Studies

Innovative approaches to treating and managing neurodegenerative conditions.

04 Immunology and Infectious Diseases

Critical research in HIV prevention and immune system modulation, including studies on transplant medicine and vaccine development for yellow fever.

HIV Pre-Exposure Prophylaxis
Transplant Immunology
Vaccine Development

Focus on preventing infectious diseases and improving transplant outcomes through immunological interventions.

Back to Germany All countries